Teva Q4 top line down 16%; Copaxone sales down 19%; non-GAAP earnings down 32%; shares down 9% premarketTeva Pharmaceutical Industries (NYSE:TEVA) Q4 results ($M):
Revenues: 5,459 (-15.9%);
Generics: 3,114 (-16.2%);
Specialty Medicines: 1,795 (-18.5%).
U.S. generics: 1,186 (-15.0%);
U.S. specialty meds: 1,165 (-32.1%).
Copaxone: 821 (-19.1%).
Net loss: (11,600) (-999%);
Non-GAAP net income: 1,014 (-31.5%);
Loss/share: (11.41) (-999%);
Non-GAAP EPS: 0.93 (-32.6%);
Cash flow ops: 1,179 (-17.3%).
Goodwill impairments of $17.1B in U.S generics business recorded in 2017.
2018 guidance: Revenues: $18.3B - 18.8B (down 17.2% from 2017);
Non-GAAP EPS: $2.25 - 2.50.
Shares are down 9% premarket on robust volume.
Source: Seeking Alpha
https://www.investing.com/news/stock-ma ... et-1215317
It's all about "how much you made when you were right" & "how little you lost when you were wrong"